Side-by-side · Research reference

PTD-DBMvsSermorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED10/40 cited

BPhase 3HUMAN-REVIEWED14/43 cited

PTD-DBM

Wnt Pathway Activator · Fusion Peptide

Topical / SQAdministrationLee 2023 Ryu 2023

Animal-onlyEvidence level

Wnt/β-cateninPrimary pathway

Topical / SQ · Study-dependent

Sermorelin

GHRH 1-29 fragment · Short-acting

100–500 mcgPer doseMolteno 2013

Phase 3Evidence levelWalker 1994 Molteno 2013

~12 minHalf-lifeMolteno 2013

SQ · Pre-sleep · 1×/day

01Mechanism of Action

Parameter

PTD-DBM

Sermorelin

Primary target

CXXC5–Dishevelled protein-protein interaction

Pituitary GHRH receptorWalker 1994

Pathway

Inhibit CXXC5 binding to Dishevelled → Release Wnt/β-catenin pathway inhibitionLee 2015 Ryu 2023

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994

Downstream effect

Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation

Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013

Feedback intact?

Not applicable — pathway derepression rather than receptor agonism

Yes — short pulse preserves feedback

Origin

Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5

Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994

Antibody development

—

02Dosage Protocols

Parameter

PTD-DBM

Sermorelin

Wound healing protocol

Hydrogel patch delivery (concentration not disclosed)

Pyrogallol-HA patch, murine model.

—

Hair regeneration protocol

Topical application (exact dose not disclosed)

Wound-induced hair neogenesis model, mice.

—

Evidence basis

Animal models only (mice)

Phase 3 (Geref pediatric); clinical practiceWalker 1994 Molteno 2013

Co-administration

Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023

Combined treatment maximized scar reduction.

—

Human translation

No published human studies

—

Standard dose

—

100–500 mcg per injectionMolteno 2013

Frequency

—

Once daily, pre-sleep

Lower / starter dose

—

100 mcg per dose

Duration

—

8–12 weeks per cycle

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep, fasted preferred

Half-life

—

~12 min (plasma)Molteno 2013

Shorter than tesamorelin (~26 min) — simpler GHRH analogue.

04Side Effects & Safety

Parameter

PTD-DBM

Sermorelin

Reported adverse events

None reported in animal studies

—

Wnt pathway activation risks

Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis

—

Long-term safety

Unknown — no chronic dosing or human data

—

Delivery vehicle effects

HA-PG hydrogel well-tolerated in mice; human translation pending

—

Injection site reaction

—

Mild erythema, transient pain

Flushing / headache

—

Common transient effect

IGF-1 elevation

—

Modest at standard doses

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Glucose handling

—

Generally neutral

Absolute Contraindications

PTD-DBM

·Active malignancy (Wnt pathway involvement in tumorigenesis)
·Pregnancy / lactation (no safety data)

Sermorelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

PTD-DBM

·History of Wnt-driven tumors
·Skin lesions with uncertain malignant potential

Sermorelin

·Untreated diabetes

05Administration Protocol

Parameter

PTD-DBM

Sermorelin

1. Wound Healing Protocol (Animal Model)

Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Hair Regeneration Protocol (Animal Model)

Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023

SQ — abdomen or thigh. Rotate sites.

3. Combination Therapy

PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023

Pre-sleep, fasted.

4. Storage & Handling

Not disclosed in available literature. Peptide stability and storage conditions not published.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

PTD-DBM

— no documented stacks

Sermorelin

+ Ipamorelin

Strong

View Ipamorelin →

Sermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.

Sermorelin: 200–300 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Raun 1998 Walker 1994